Work in progress should produce within the next few years a better understanding of the nature of immune responses to human cancer antigens. Studies to date, notably with melanomas, have shown that many, perhaps most, are immunogenic. However, the antibodies elicited are often not specific to tumor antigens. At this point, neither uncritical optimism nor paralyzing pessimism is justified.